|Day Low/High||40.15 / 40.38|
|52 Wk Low/High||36.41 / 42.47|
These themes are working despite the turmoil in Washington and slowing global growth.
So far 2019 is proving to be a year where things have a habit of working out right.
One of pharma's biggest CEO's talks M&A action on the exchange.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Strong balance sheet and royalties are big positives for Innoviva.
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
GSK is still below the declining 200-day moving average line but a rally of $2 will challenge the line.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Pfizer is reportedly planning to sell its consumer healthcare business in an auction next month
European stock markets are priced almost to perfection ahead of an earnings deluge.
You would think that Nascar champion Danica Patrick would be a gear head who can talk makes, models and car parts and and car collector with garages brimming with rare autos. You would be wrong.
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
You don't want to own these four 'toxic stocks'.
Technical indicators suggest GSK can see further significant gains in 2017.
Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.
After another technical look at GSK, this FTSE component is still going strong.